NI201100052A - Derivados de picolinamida como inhibidores de cinasa. - Google Patents
Derivados de picolinamida como inhibidores de cinasa.Info
- Publication number
- NI201100052A NI201100052A NI201100052A NI201100052A NI201100052A NI 201100052 A NI201100052 A NI 201100052A NI 201100052 A NI201100052 A NI 201100052A NI 201100052 A NI201100052 A NI 201100052A NI 201100052 A NI201100052 A NI 201100052A
- Authority
- NI
- Nicaragua
- Prior art keywords
- kinase
- compositions
- compounds
- kinase inhibitors
- picolinamide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
Los nuevos compuestos de picolinamide, sus composiciones y usos para la inhibición de la integración de quinasa de Provirus de Maloney ( PIM quinasa ) y su actividad asociada con la tumorigénesis se proporcionan en un sujeto humano o animal. En ciertas realizaciones, los compuestos y composiciones son eficaces para inhibir la actividad de al menos un PIM quinasa. Los nuevos compuestos y composiciones se pueden utilizar solos o en combinación con al menos un agente adicional para el tratamiento de una serina / treonina quinasa -o desorden-tirosina del receptor de quinasa mediada como el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9366608P | 2008-09-02 | 2008-09-02 | |
US22566009P | 2009-07-15 | 2009-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201100052A true NI201100052A (es) | 2011-09-03 |
Family
ID=41228825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201100052A NI201100052A (es) | 2008-09-02 | 2011-03-01 | Derivados de picolinamida como inhibidores de cinasa. |
Country Status (39)
Country | Link |
---|---|
US (4) | US8329732B2 (es) |
EP (1) | EP2344474B1 (es) |
JP (2) | JP5412519B2 (es) |
KR (1) | KR101345920B1 (es) |
CN (3) | CN104311480A (es) |
AU (1) | AU2009289319C1 (es) |
BR (1) | BRPI0918268B1 (es) |
CA (1) | CA2734415C (es) |
CL (1) | CL2011000454A1 (es) |
CO (1) | CO6351725A2 (es) |
CR (1) | CR20110114A (es) |
DK (1) | DK2344474T3 (es) |
DO (1) | DOP2011000067A (es) |
EA (1) | EA020136B1 (es) |
EC (1) | ECSP11010859A (es) |
ES (1) | ES2551900T3 (es) |
GE (1) | GEP20135849B (es) |
HK (2) | HK1156627A1 (es) |
HN (1) | HN2011000629A (es) |
HR (1) | HRP20151410T1 (es) |
HU (1) | HUE026381T2 (es) |
IL (1) | IL211291A (es) |
MA (1) | MA32684B1 (es) |
ME (1) | ME01291A (es) |
MX (1) | MX2011002365A (es) |
MY (1) | MY150136A (es) |
NI (1) | NI201100052A (es) |
NZ (1) | NZ591449A (es) |
PE (1) | PE20110298A1 (es) |
PL (1) | PL2344474T3 (es) |
PT (1) | PT2344474E (es) |
RS (1) | RS54506B1 (es) |
SI (1) | SI2344474T1 (es) |
SM (1) | SMT201600005B (es) |
SV (1) | SV2011003849A (es) |
TW (1) | TWI434843B (es) |
UY (1) | UY32085A (es) |
WO (1) | WO2010026124A1 (es) |
ZA (1) | ZA201101118B (es) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2348023B9 (en) | 2005-12-13 | 2017-03-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US20140249135A1 (en) * | 2007-03-01 | 2014-09-04 | Novartis Ag | Pim kinase inhibitors and methods of their use |
CN101932582B (zh) | 2007-06-13 | 2013-09-25 | 因塞特公司 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
AU2009289316A1 (en) * | 2008-09-02 | 2010-03-11 | Novartis Ag | Bicyclic kinase inhibitors |
EP2344474B1 (en) | 2008-09-02 | 2015-09-23 | Novartis AG | Picolinamide derivatives as kinase inhibitors |
SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
CN102458581B (zh) | 2009-05-22 | 2016-03-30 | 因塞特控股公司 | 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物 |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
ME02386B (me) | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
PE20130405A1 (es) * | 2010-04-07 | 2013-04-10 | Hoffmann La Roche | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso |
KR102303885B1 (ko) | 2010-05-21 | 2021-09-24 | 인사이트 홀딩스 코포레이션 | Jak 저해제에 대한 국소 제형 |
US20130109682A1 (en) * | 2010-07-06 | 2013-05-02 | Novartis Ag | Cyclic ether compounds useful as kinase inhibitors |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
EP2640723A1 (en) | 2010-11-19 | 2013-09-25 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
US9284270B2 (en) | 2011-02-14 | 2016-03-15 | The Governers Of The University Of Alberta | Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids |
UY33929A (es) * | 2011-03-04 | 2012-10-31 | Novartis Ag | Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas |
UY33930A (es) * | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
US9187486B2 (en) | 2011-04-29 | 2015-11-17 | Amgen Inc. | Bicyclic pyridazine compounds as Pim inhibitors |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
US9453003B2 (en) * | 2011-08-11 | 2016-09-27 | Jikai Biosciences, Inc. | Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
US9458151B2 (en) * | 2011-08-11 | 2016-10-04 | Jikai Biosciences, Inc. | Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
AU2013264831B2 (en) * | 2012-05-21 | 2016-04-21 | Novartis Ag | Novel ring-substituted N-pyridinyl amides as kinase inhibitors |
WO2014033630A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | Novel aminothiazole carboxamides as kinase inhibitors |
WO2014033631A1 (en) | 2012-08-31 | 2014-03-06 | Novartis Ag | N-(3-pyridyl) biarylamides as kinase inhibitors |
HUE049611T2 (hu) | 2012-09-26 | 2020-09-28 | Hoffmann La Roche | Ciklikus éter-pirazol-4-il-heterociklil-karboxamid vegyületek és felhasználási módszerek |
CN103724301A (zh) * | 2012-10-10 | 2014-04-16 | 上海特化医药科技有限公司 | (2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途 |
EA201590930A1 (ru) | 2012-11-15 | 2015-08-31 | Инсайт Корпорейшн | Лекарственные формы руксолитиниба с замедленным высвобождением |
US20150336960A1 (en) | 2012-12-19 | 2015-11-26 | Novartis Ag | Aryl-substituted fused bicyclic pyridazine compounds |
WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
SG11201505347VA (en) | 2013-01-15 | 2015-08-28 | Incyte Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
JP6397831B2 (ja) | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤の製造方法及びその中間体 |
US9113629B2 (en) * | 2013-03-15 | 2015-08-25 | Dow Agrosciences Llc | 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
CN105611928A (zh) | 2013-08-08 | 2016-05-25 | 诺华股份有限公司 | Pim激酶抑制剂组合 |
US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
EP3074043A1 (en) * | 2013-11-27 | 2016-10-05 | Novartis AG | Combination therapy comprising an inhibitor of jak, cdk and pim |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
KR20220126813A (ko) | 2014-03-14 | 2022-09-16 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
RU2016137761A (ru) | 2014-03-18 | 2018-04-18 | Ф. Хоффманн-Ля Рош Аг | Оксепан-2-ил-пиразол-4-ил-гетероциклил-карбоксамиды и способы их применения |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
EP3659621A1 (en) | 2014-09-13 | 2020-06-03 | Novartis AG | Combination therapies for cancer |
BR112017006664A2 (pt) | 2014-10-03 | 2017-12-26 | Novartis Ag | terapias de combinação |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
JP6692826B2 (ja) | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
PL3317301T3 (pl) | 2015-07-29 | 2021-11-15 | Novartis Ag | Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3 |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
CN105254624B (zh) * | 2015-09-18 | 2019-08-09 | 上海吉铠医药科技有限公司 | 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用 |
CN105130959B (zh) * | 2015-09-18 | 2018-08-03 | 上海吉铠医药科技有限公司 | 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用 |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
RS63125B1 (sr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Antitela koja se specifično vezuju za pd-1 i njihova upotreba |
AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
CN107522695B (zh) * | 2016-06-21 | 2018-09-14 | 上海方予健康医药科技有限公司 | 一种pim激酶抑制剂的盐酸盐及其制备方法和用途 |
CN107522696B (zh) * | 2016-06-21 | 2019-02-19 | 上海方予健康医药科技有限公司 | 一种嘧啶类化合物的盐酸盐及其制备方法和用途 |
CN107519175A (zh) * | 2016-06-21 | 2017-12-29 | 上海方予健康医药科技有限公司 | 一种嘧啶化合物或其盐在制备用于预防和/或治疗与flt3相关的疾病或障碍的药物中的应用 |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
SG11201911936YA (en) * | 2017-06-30 | 2020-01-30 | Bristol Myers Squibb Co | Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CR20200379A (es) | 2018-01-30 | 2021-03-05 | Incyte Corp | Procesos e intermedio para elaborar un inhibidor de jak campo técnico |
PT3762368T (pt) | 2018-03-08 | 2022-05-06 | Incyte Corp | Compostos de aminopirazina diol como inibidores de pi3k-y |
CA3095487A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
CA3095580A1 (en) | 2018-04-13 | 2019-10-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
CN110078706B (zh) * | 2019-05-31 | 2022-02-01 | 浙江师范大学 | 一种伊马替尼衍生物及其制备方法和用途 |
CN110452164B (zh) * | 2019-09-10 | 2022-07-22 | 上海皓鸿生物医药科技有限公司 | Pim447关键中间体的制备方法 |
US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
EP4054583A4 (en) * | 2019-11-07 | 2023-10-25 | Crinetics Pharmaceuticals, Inc. | MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND THEIR USES |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN112915086B (zh) * | 2021-01-27 | 2022-04-12 | 广州市力鑫药业有限公司 | 一种含有Akt靶向激酶抑制剂的药物组合物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2398478A1 (en) | 2000-01-26 | 2001-08-02 | Kunio Atsumi | Novel quaternary salt-type carbapenem derivatives |
CA2397493A1 (en) | 2000-01-27 | 2001-08-02 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US8618085B2 (en) | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
KR100557093B1 (ko) | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
PE20050444A1 (es) | 2003-10-31 | 2005-08-09 | Takeda Pharmaceutical | Compuestos de piridina como inhibidores de la peptidasa |
US7592340B2 (en) | 2003-12-04 | 2009-09-22 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
US20060004197A1 (en) | 2004-07-02 | 2006-01-05 | Thomas Thrash | Sulfonamide-based compounds as protein tyrosine kinase inhibitors |
CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
EP1909910A1 (en) | 2005-08-04 | 2008-04-16 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
WO2007044724A2 (en) | 2005-10-06 | 2007-04-19 | Exelixis, Inc. | Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3 |
GB0520657D0 (en) * | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
HRPK20050957B3 (en) * | 2005-11-11 | 2008-09-30 | Džanko Nikša | Collapsible hanger |
KR20090082440A (ko) * | 2006-10-31 | 2009-07-30 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 2-아미노티아졸-4-카복실산 아미드 |
US9206142B2 (en) | 2006-10-31 | 2015-12-08 | Merck Sharp & Dohme Corp. | Anilinopiperazine derivatives and methods of use thereof |
US8822497B2 (en) * | 2007-03-01 | 2014-09-02 | Novartis Ag | PIM kinase inhibitors and methods of their use |
WO2009014637A2 (en) | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
NZ583790A (en) | 2007-09-10 | 2012-04-27 | Cipla Ltd | Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process |
PE20091577A1 (es) * | 2008-03-03 | 2009-11-05 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
EP2344474B1 (en) | 2008-09-02 | 2015-09-23 | Novartis AG | Picolinamide derivatives as kinase inhibitors |
WO2011016234A1 (en) | 2009-08-04 | 2011-02-10 | Raqualia Pharma Inc. | Picolinamide derivatives as ttx-s blockers |
US8859546B2 (en) | 2011-01-21 | 2014-10-14 | Abbvie Inc. | Picolinamide inhibitors of kinases |
-
2009
- 2009-08-31 EP EP09782396.7A patent/EP2344474B1/en active Active
- 2009-08-31 EA EA201100425A patent/EA020136B1/ru not_active IP Right Cessation
- 2009-08-31 MX MX2011002365A patent/MX2011002365A/es active IP Right Grant
- 2009-08-31 PT PT97823967T patent/PT2344474E/pt unknown
- 2009-08-31 CN CN201410461060.3A patent/CN104311480A/zh active Pending
- 2009-08-31 WO PCT/EP2009/061205 patent/WO2010026124A1/en active Application Filing
- 2009-08-31 SI SI200931330T patent/SI2344474T1/sl unknown
- 2009-08-31 BR BRPI0918268-3A patent/BRPI0918268B1/pt active IP Right Grant
- 2009-08-31 AU AU2009289319A patent/AU2009289319C1/en active Active
- 2009-08-31 CN CN200980143187.8A patent/CN102203079B/zh active Active
- 2009-08-31 CN CN2013102514039A patent/CN103333157A/zh active Pending
- 2009-08-31 CA CA2734415A patent/CA2734415C/en active Active
- 2009-08-31 NZ NZ591449A patent/NZ591449A/xx not_active IP Right Cessation
- 2009-08-31 MY MYPI2011000927A patent/MY150136A/en unknown
- 2009-08-31 KR KR1020117007556A patent/KR101345920B1/ko active IP Right Grant
- 2009-08-31 GE GEAP2009012163 patent/GEP20135849B/en unknown
- 2009-08-31 ME MEP-2011-37A patent/ME01291A/me unknown
- 2009-08-31 PE PE2011000444A patent/PE20110298A1/es active IP Right Grant
- 2009-08-31 PL PL09782396T patent/PL2344474T3/pl unknown
- 2009-08-31 JP JP2011524408A patent/JP5412519B2/ja active Active
- 2009-08-31 RS RS20150730A patent/RS54506B1/en unknown
- 2009-08-31 ES ES09782396.7T patent/ES2551900T3/es active Active
- 2009-08-31 DK DK09782396.7T patent/DK2344474T3/en active
- 2009-08-31 HU HUE09782396A patent/HUE026381T2/en unknown
- 2009-08-31 US US12/584,158 patent/US8329732B2/en active Active
- 2009-09-01 UY UY0001032085A patent/UY32085A/es not_active Application Discontinuation
- 2009-09-01 TW TW098129413A patent/TWI434843B/zh not_active IP Right Cessation
-
2011
- 2011-02-11 ZA ZA2011/01118A patent/ZA201101118B/en unknown
- 2011-02-17 IL IL211291A patent/IL211291A/en active IP Right Grant
- 2011-03-01 CL CL2011000454A patent/CL2011000454A1/es unknown
- 2011-03-01 NI NI201100052A patent/NI201100052A/es unknown
- 2011-03-02 DO DO2011000067A patent/DOP2011000067A/es unknown
- 2011-03-02 HN HN2011000629A patent/HN2011000629A/es unknown
- 2011-03-02 CR CR20110114A patent/CR20110114A/es unknown
- 2011-03-02 EC EC2011010859A patent/ECSP11010859A/es unknown
- 2011-03-03 SV SV2011003849A patent/SV2011003849A/es unknown
- 2011-03-08 CO CO11028419A patent/CO6351725A2/es active IP Right Grant
- 2011-04-01 MA MA33733A patent/MA32684B1/fr unknown
- 2011-10-17 HK HK11111043.1A patent/HK1156627A1/xx not_active IP Right Cessation
- 2011-12-15 US US13/327,358 patent/US8592455B2/en active Active
-
2012
- 2012-03-06 HK HK12102246.4A patent/HK1162022A1/xx not_active IP Right Cessation
-
2013
- 2013-06-25 JP JP2013132978A patent/JP5813701B2/ja active Active
- 2013-11-15 US US14/081,132 patent/US9079889B2/en active Active
-
2015
- 2015-07-13 US US14/797,534 patent/US20150315150A1/en not_active Abandoned
- 2015-12-22 HR HRP20151410TT patent/HRP20151410T1/hr unknown
-
2016
- 2016-01-05 SM SM201600005T patent/SMT201600005B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201100052A (es) | Derivados de picolinamida como inhibidores de cinasa. | |
NI200800060A (es) | Bencimidazoles sustituidos como inhibidores de cinasa. | |
MX2009009304A (es) | Inhibidores de cinasa pim y metodos para su uso. | |
CL2009001058A1 (es) | Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras. | |
EA201100427A1 (ru) | Гетероциклические ингибиторы киназы | |
NI201000156A (es) | Compuestos heterocíclicos novedosos y usos de los mismos. | |
GT200800158A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
EA201100426A1 (ru) | Бициклические ингибиторы киназы | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
CL2012000583A1 (es) | Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras. | |
DOP2013000027A (es) | Derivados de tetrahidro-pirido-pirimidina | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
CL2022002148A1 (es) | Inhibidores heterocíclicos de pad4 | |
PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
CR20110332A (es) | Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida | |
CU23997B1 (es) | Derivados de picolinamida como inhibidores de cinasa | |
TN2011000070A1 (en) | Picolinamide derivatives as kinase inhibitors | |
JO3055B1 (ar) | مشتقات بيكوليناميد كمثبطلت كيناز | |
CU23534B7 (es) | Nuevos derivados de 4-bencilidenpiperidina | |
CL2011002626A1 (es) | Compuestos derivados de piperazina, como antagonistas del receptor p2y12; composicion farmaceutica que los contienen; y su uso en el tratamiento de trastornos vasculares oclusivos. | |
CU20100182A7 (es) | Compuestos heterocíclicos novedosos y usos de los mismos | |
TH117380A (th) | สารยับยั้งไคเนสและวิธีการใช้สารเหล่านั้น | |
AR070452A1 (es) | Uso, composiciones, kits y metodos de un programa de titulacion para compuestos de pardoprunox |